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Abstract 
Despite the wealth of encouraging data from numerous compounds that demonstrate 
“neuroprotection” in pre-clinical studies of Parkinson’s disease, and despite numerous clinical trials, 
to date, no intervention has been demonstrated to able to modify the course of disease progression.  
While this “failure to translate” is likely due to numerous factors including our incomplete 
understanding of the pathogenic mechanisms underlying PD together with excessive reliance on 
data from the toxin-based animal models of PD, here we will discuss the “structural issues” 
pertaining to inadequate clinical trial design, selection of inappropriate endpoints and poor patient 
selection which are often not addressed following failed disease modification trials.  Future 
directions to overcome these challenges such as reducing the heterogeneity of patient cohorts, 
identifying and utilising a pre-diagnostic population, embracing a personalised medicine approach 
and utilising novel trial designs may be required to ultimately fulfil the goal of conclusively 
demonstrating evidence of disease modification.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Despite the development of several effective pharmacological and surgical therapies for the 
treatment of Parkinson’s disease (PD), the ultimate goal of slowing of disease progression has not 
been met.  Over time motor symptoms of tremor, rigidity and bradykinesia are invariably 
complicated by continued degeneration of non-dopaminergic systems leading to mood and 
behavioural issues, dementia and postural instability leading to worsening functional disability and 
self-care.  Pre-clinical studies have focused on halting or preventing this dopaminergic cell loss and 
numerous “neuroprotective” compounds have been demonstrated with the hope that these 
properties will translate to human subjects and slow the progression of symptoms and modify the 
expected disease course.  However, despite the promise of many therapies in pre-clinical trials, no 
disease modifying trials conducted to date have conclusively demonstrated evidence of disease 
modification. 
This general “failure to translate” is likely related to numerous factors including our incomplete 
understanding of the pathogenic mechanisms underlying PD together with excessive reliance on 
data from toxin-based animal models of PD to judge which agents to take to double blind clinical 
trial evaluation.  Detailed discussion of these factors is outside the scope of this article and will not 
be discussed here (see [1] for review).   
Inherent errors in data collection when conducting clinical trials are mostly unavoidable and often 
result in diluted effects, the need for larger sample sizes and increased costs.  However, “structural 
errors” pertaining to inadequate trial design, selection of inappropriate endpoints, poor patient 
selection, or mishandling of missing data, can be minimised and increase the chance of detecting 
true disease modifying effects [2,3].  This review will consider methodological issues relating to 
detecting efficacy in disease modification phase III trials and suggest future directions that are being 
explored that may improve the ability to detect any signal of effect.  Earlier stages in drug 
development and clinical trials present their own specific challenges and these will not be addressed 
(see [4,5] for review).    
Target population for clinical trials- embracing personalised medicine 
PD patients exhibit remarkable heterogeneity - studies suggest that different pathophysiological 
mechanisms relate to different clinical subtypes and this disease heterogeneity can influence disease 
progression [6,7]. Therefore it may seem somewhat counter-intuitive to gather such a 
heterogeneous group of patients and expect a uniform response to a particular intervention.  
Nevertheless, in all disease modifying trials to date this has been the general approach.  
Common methods of refining patient selection are to recruit patients only at a specific stage of 
disease, although this is by no means a way of predicting subsequent rates of disease progression. 
Nevertheless, in considering patient recruitment to trials of potential disease modifying 
interventions, patients can be divided into two categories – early untreated “de-novo” symptomatic 
patients and those patients on stable dopaminergic treatment that experience disability – both of 
which have merits and disadvantages for inclusion into disease modifying trials (Table 1).   
Another factor when selecting patients is that motor progression in PD is not linear and is thought to 
occur in phases.  Factors such as age of onset, predominant motor phenotype and presence of non-
motor symptoms can influence disease severity at presentation, rate of disease progression, and 
most importantly, response to treatment [8], suggesting the existence of various sub-types of PD.  
These baseline differences are often not always appreciated when incorporating data into the 
primary outcome.   
Future directions - improving patient selection and stratification for clinical trials-  
Reducing heterogeneity of cohorts 
Methods to reduce the heterogeneity of patient populations and enable the prediction of rates of 
disease progression may reduce inherent variability that currently exists between individual 
participants in a trial and thus increase its statistical power, in turn enabling more efficient and cost-
effective collection of data and increase the likelihood of detecting a signal of effect.   
Although there are ongoing efforts to identify PD subtypes, well-defined criteria have not yet been 
widely accepted, but by using clinical, biochemical or genetic markers (or a combination) researchers 
may be able to improve patient stratification for inclusion of more homogeneous cohorts into future 
trials (Figure 1).   
Basic clinical markers (i.e. motor phenotype) can be potentially useful to predict disease progression. 
Analysis of data from the Parkinson’s Progression Markers Initiative (PPMI) database suggests that 
older age of onset is associated with a more severe motor and non-motor phenotype, greater 
dopaminergic dysfunction on DaTSCAN, and reduction of CSF alpha synuclein and total tau [9]. 
Similarly tremor-dominant PD is associated with slower disease progression and less-severe 
cognitive impairment than akinetic-rigid PD [10], while a recent study demonstrated that the 
presence of mild cognitive impairment, orthostatic hypotension and REM Sleep behaviour disorder 
at baseline is associated with a more malignant disease course [11]. Building on this, a recent model 
has been validated that allows individual patient prognostication.  Based on 3 predictor variables, 
namely  higher patient age, higher Unified Parkinson's Disease Rating Scale motor examination axial 
score, and a lower verbal fluency score for animals at baseline, patients can be reliably predicted to 
be more likely to develop non-levodopa responsive symptoms of dementia and postural instability at 
5 years from diagnosis [12]. These simple variables could be used to create a more homogenous 
cohort with a predictable disease course.  
Clinical markers may however be unstable in early disease and may also be substantially influenced 
by symptomatic therapy [13].  Recent studies suggest that biochemical markers may be able to more 
precisely identify molecular subtypes that have differential responses to treatment.  A recent study 
suggested that patients with low levels of Aβ1-42 or highest t-tau/Aβ1-42 had more severe non 
motor dysfunction, whereas lower alpha-synuclein levels were associated with worse cognitive 
performance [14] and therefore may potentially be useful to predict patient subgroups likely to have 
accelerated disease progression.  Similarly, the presence of high levels of pro-inflammatory immune 
markers in patient serum is associated with more rapid motor progression and lower MMSE scores 
[15]. 
Precision / personalised medicine 
Additionally, identification of genes involved in familial PD has suggested that distinct 
pathophysiology could also underlie different forms of PD [16] and also affect clinical phenotype and 
motor progression [17]. This may allow trials to offer “personalised” interventions that specifically 
target an aspect of PD disease pathophysiology known to be abnormal in individual patients and 
recruit patients accordingly, increasing the chance of influencing disease progression.  A recent study 
using neural cells generated from induced pluripotent stem cells derived from PD patients and pre-
symptomatic individuals carrying mutations in the PINK1 (PTEN-induced putative kinase 1) and 
LRRK2 (leucine-rich repeat kinase 2) genes [18] analysed the subsequent cellular responses when 
treated with potential neuroprotective agents coenzyme Q10, rapamycin and LRRK2 inhibitors.  The 
study indicated that treatments had varying levels of effectiveness, depending on the genetic 
mutation involved; for example rapamycin reduced oxidative stress and mitochondrial stress in 
LRRK2 mutant neural cells but not in PINK1 patient neural cells.  This technology could be used to 
predict drug efficacy, and identify potential drug-responsive cohorts for selection in clinical trials.   
A precision or personalised medicine approach in combination with genetic and epigenetic testing is 
commonplace in patient selection for cancer clinical trials and has yielded numerous successes. 
Patients with breast cancer that overexpress human epidermal growth factor receptor 2 (HER2) have 
been found to not respond to standard therapy but by studying a homogenous population all with 
this particular mutation, it has been found that trastuzumab, a monoclonal antibody can be effective 
in this particular subgroup [19].   
Similarly, this approach is starting to be utilised in PD clinical trials.  Mutations in the gene encoding 
glucocerebrosidase (GBA) constitute the most frequent risk factor for PD in the general population, 
and the presence of a mutation in GBA confers a worse prognosis to PD patients.  Studies show that 
GBA mutations are associated with reduced glucosylceramidase activity and oxidative stress while 
simultaneously it has been demonstrated that ambroxol, a secretolytic agent licensed for the 
treatment of respiratory diseases, can increase glucosylceramidase activity and reduce alpha-
synuclein levels in pre-clinical models [20].  A small clinical trial specifically recruiting patients with 
mutations in the GBA gene is currently underway to assess the safety and dosing range of ambroxol 
and represents a novel method of selective recruitment based on possible mechanism of action. 
However it remains to be seen whether highly targeted drugs or drugs that target different systems 
will be most successful.   
As with all these possible methods, uncertainty remains regarding the extrapolation of such results 
in a wider heterogeneous population and so further studies may have to be explored to assess the 
response in a more heterogeneous population.  
Maximising neuroprotective potential 
Trials that select patients with “early” or untreated disease are commonly recruited to maximise any 
possible neuroprotective effects however, even in this population neurodegeneration may be 
substantially advanced by the time of diagnosis.  A study quantifying the extent of nigrostriatal 
degeneration at varying stages of PD 1 to 27 years post diagnosis demonstrated that tyrosine 
hydroxylase-positive neurons in the fibres of the dorsal putamen are already reduced at diagnosis, 
and are virtually absent as early as 4 years after diagnosis [21].   Therefore identifying and recruiting 
patients at the very earliest stages or even prior to neurodegeneration may represent a better 
strategy.  Studies suggest the onset of PD can begin up to 20 years prior to appearance of classical 
motor symptoms while data from imaging studies utilising PET and SPECT suggest nigrostriatal 
degeneration can be detected approximately 5-10 years before the appearance of classical motor 
symptoms [22,23].  This pre-diagnostic period includes completely asymptomatic individuals at risk 
of developing PD (“pre-clinical”) as well as those patients exhibiting mild motor and non-motor 
symptoms although insufficient for a diagnosis of PD (“pro-dromal”).  The pre-diagnostic population 
represents an appealing group for inclusion as any disease modifying therapy could maximise 
benefits by potentially delaying or completely preventing the onset of overt disease, by preserving 
greater number of neurons and preventing secondary self-propagating degenerative processes. 
However, accurately identifying this pre-diagnostic population is very difficult.  Although 
environmental factors such as exposure to pesticides and heavy metals such as manganese, and 
lifestyle factors such as avoidance of smoking, caffeine and alcohol have all been associated with an 
increased risk of PD [24], the low predictive values and relevance of these factors hinder their utility 
in identifying patients in longitudinal studies.  Even in patients with a single identifiable strong risk 
factor for PD such as idiopathic RBD, being a LRRK2 carrier or possessing a GBA mutation, there is 
wide variability of conversion to manifest disease[25,26].   
Prodromal PD describes the stage in the natural history of PD wherein patients exhibit subtle motor 
and non-motor symptoms and signs but which are insufficient to diagnose PD.   Patients in the 
prodromal stage of PD offer similar advantages as the “at risk” population to researchers of disease 
modifying trials, however similar issues with the accurate identification of these patients also exist.  
Recently, a task force from the MDS developed research diagnostic criteria for the prodromal phase 
of PD based on the presence or absence of certain risk factors such as sex, RBD, depression, 
abnormal substantia nigra echogenicitiy etc. These criteria were recently successfully applied 
retrospectively to a longitudinal study cohort of elderly patients with a sensitivity of ‘probable 
prodromal PD’ status for incident PD of 54.6% (95% confidence interval, 28.0–78.8) and specificity of 
99.2% (97.8–99.8), indicating that it may be useful in defining target populations for disease 
modifying trials.   
However, limited accessibility to specialised functional imaging and diagnostic techniques such as 
polysomnography may limit identification of this population, though if patients could be reliably 
identified, there remain new issues with regards to selecting an appropriate endpoint.   
The first appearance of motor dysfunction as detected by the MDS-UPDRS may indicate appearance 
of disease onset (and has been used as an endpoint in premanifest Huntington’s disease trials), 
however mild elevation in MDS-UPDRS Part III scores (2-10) can occur in the general population and 
increases with age [27], making interpretation difficult.  Conversion to overt PD could in theory be 
used as an endpoint. Given there is a only low risk of incident PD (1.67% of individuals over 50yrs 
after 5 years in a recent observational study [28]), trials would have to recruit extremely large 
numbers of healthy individuals and have unfeasibly long follow up periods to be able to detect even 
a large risk reduction from any disease modifying therapy [26].  In contrast, enriching patient cohorts 
with individuals with a high combination of risk factors that influence disease progression (such as 
patient with idiopathic RBD, hyposmia, and  with abnormal DAT-SPECT imaging) may increase the 
incidence of subsequent PD diagnosis and hence reduce the number of participants required to 
adequately power a trial of a potential disease modifying therapy [26]. Though currently this would 
still likely require large numbers of patients followed up for a number of years to detect a small 
reduction in PD risk.  Furthermore, there are inevitable ethical concerns in informing individuals that 
they are at high risk of developing PD, especially while no disease modifying therapies currently 
exist, and strategies to deal with this might include blinded inclusion of both high risk and a subset of 
low risk patients. 
A significant issue with utilising a pre-diagnostic population in an interventional trial is that exposing 
asymptomatic or minimally affected individuals to novel therapies with potential adverse effects 
may induce high patient drop out.  Additionally, there remains the inherent difficulty of assessing 
the long-term safety of these new treatments, which may target molecular mechanisms involved in 
other diseases.  For example, efforts to target the toxic effects of alpha-synuclein aggregation as a 
disease modifying strategy using passive and active immunisation with monoclonal antibodies 
against alpha-synuclein have been found safe in phase 1 trials [29].  However there are theoretical 
concerns that some species of alpha-synuclein may be protective [30] and the long term 
consequences of lowering alpha-synuclein may have unforeseen outcomes [29].  Alternatively using 
drugs already in clinical use with well-known safety and pharmacokinetic profiles and “re-
positioning” them for use in PD may allay some of the short term safety concerns but often long 
term safety data regarding their use in a novel population (e.g. PD patients) is lacking.   
 
Clinical trial design 
Although previous trials have putatively reported potential disease modifying effects 
[31,32],controversy remains due to significant difficulties in being able to distinguish between any 
symptomatic effects of the therapy and any true disease modifying effects. There are a number of 
approaches to trial design that have attempted to disentangle these mechanisms, each with their 
own advantages and disadvantages. 
Washout studies involve a two period design that includes a “washout” phase at the end of the 
study (whereby the intervention is withdrawn) prior to the final assessment of the patient and 
evaluates the change in Parkinson’s disease rating scale scores.  Any benefit seen in the active arm 
that persists over the washout period may indicate evidence of disease modification.  This approach 
has been previously used to assess deprenyl (Selegiline) vs placebo [33] and levodopa vs placebo 
(ELLDOPA)[32] on disease progression in PD.  However, although both trials seemed to indicate 
persistent beneficial effects after the washout period, many have questioned the validity of the 
results and subsequently regulatory approval of these drugs as disease modifiers has not been 
accepted.  An inherent issue with this design is that is if the washout period is too short, uncertainty 
remains regarding whether any of the persistent beneficial effects seen could be due to 
unanticipated long-lasting symptomatic effects.  Washout periods are typically calculated as some 
multiple of the half-life of the pharmaceutical product within the population of interest; however 
this may not always be the most optimum method.  The ELLDOPA trial utilised a washout period of 
14 days, initially thought to be sufficient based on the half-life of levodopa (90minutes), however, it 
is now known that symptomatic effects of levodopa can still be detectable up to 32 days after 
withdrawal [34].  Additionally, differential bias may occur in the evaluation of those declining more 
rapidly in the washout phase.  Alternatively, using a long washout period of several months to 
ensure loss of symptomatic effects could result in a confound by the progressive nature of PD,  
induce significant lessebo effects [35] and risk high levels of patient dropout in untreated patients, 
and may have ethical considerations.    
Delayed-start designs are a promising alternative to wash out studies and comprise a similar two 
period design.  The first period involves patients randomised to either placebo or active intervention 
followed by the second period whereby both groups receive the active intervention and are followed 
up for a fixed time period.  Exposing patients to placebo at the start of the trial combined with all 
participants eventually being exposed to active intervention may improve subject recruitment and 
retainment and may minimise any lessebo effects in the second period.  Although there is no agreed 
statistical method for analysis and interpretation of the data for delayed start designs, the most 
common method used to identify evidence of disease modification relies on analysis of 3 
components in sequence – the superiority of treatment over placebo during the first period; the non 
inferiority of early vs. delayed start (i.e. that slopes during the second phase comparing both groups 
on active treatment do not converge); and that there remains a significant difference between the 
two groups at the end of the study period[36].  Analysis of the data requires complex statistical 
analysis and multiple hypotheses in a sequential manner, but this design has been used successfully 
in a number of trials assessing the disease modifying effects of rasagiline (TEMPO[37], ADAGIO[31]), 
pramipexole (PROUD[38]) and deferiprone (FAIRPARK[39]) and remains of great interest to 
researchers [40].  However, there are a number of problems with this design. The initial period has 
to long enough for any neuroprotective effects to be detected, typically estimated at 6-12 months 
(which also raises ethical concerns of (potentially drug-naïve) patients remaining on placebo for a 
long period and risks high patient drop out, leading to an over representation of individuals with 
minimally progressive symptoms).  Delayed start designs must be powered to detect small changes 
in UPDRS, and while the relevance of such small changes is uncertain, they also generally need 
longer follow up to ascertain whether any differences is sustained.  For example, the minimal change 
in total UPDRS score thought to represent a clinically meaningful improvement for patients is around 
5-8 points [41–43] and the ADAGIO[31] and TEMPO[37] trials demonstrated a difference of around 2 
UPDRS points between delayed start and early start groups.  In the FAIRPARK trial, small differences 
between the delayed start and early start groups waned after a longer follow up, calling into 
question the relevance of such small differences [39].   Also, although the design of the trial is 
“double-blind”, as the second period involves all participants on the active intervention, it is 
questionable whether the blind can be fully preserved.    
An alternatively used approach are trials not focused on differentiating symptomatic from disease 
modifying changes but rather changes in long term disability (“milestones”) that are clinically 
meaningful.  Longitudinal study “single-period” designs use composite global measures assessing a 
range of motor and non-motor symptoms for a multidimensional assessment of disease progression 
over a long time period, typically a number of years, are considered most effective in assessment of 
disease-modifying therapies.  Patients could be recruited all varying stages of the disease, however 
such trials require considerable investment and extensive collaboration between pharma 
companies, research institutes and clinical centres to manage the often substantial costs. 
Futility trials can be used to screen out therapies unlikely to prove efficacious in larger phase III 
studies and use a short term outcome to compare the treatment group against a historical control 
(with therapies considered futile if alpha is greater than 0.10 or 0.15 (a P value less stringent than 
typically accepted to reduce sample size and false negatives), thus requiring a fraction of the 
patients and resources used in more conventional studies [44].   However, a major limitation is that 
the choice of data used to compare futility must be carefully considered as historical controls have 
been shown to behave differently from modern placebo groups [45] and so more recent trials have  
utilised a concurrent placebo group to overcome this confound [46] – however this may eliminate 
many of the futility designs’ original advantages.    
Adaptive designs utilise interim analysis to modify the course of a study without affecting the 
integrity of the trial.  Newly available, high quality evidence can be incorporated into the study 
design allowing for alteration of sample size based on observed variability, modifying ineffective 
doses, moving patients among various trial phases, or simply ending a trial early due to failure of 
efficacy (such as in the case of NET-PD and PRECEPT studies [47,48]).  Although these designs can 
improve efficiency and reduce drug development time, they may introduce bias, require complex 
operational support from statisticians and safety monitoring boards in order to make real time 
decisions based on current data [2,49].  Additionally, in both futility and adaptive designs, 
characterising a response as “positive” or “negative” in a relatively short time period in a such a 
slowly progressive condition as PD can be challenging. 
Future directions – improving data collection and trial design 
Selecting the appropriate trial design, reducing the inherent variability of data collection and utilising 
novel methods will be essential for maximising the potential to detect any positive signal of effect 
and may reduce the often prohibitive costs of clinical trials of putative disease modifying agents 
(Figure 2).   
Trial design and disease modelling 
It must be emphasised that properly randomised, double-blind, placebo controlled trials currently 
remain the most accepted standard for assessing disease modification in clinical trials.  However 
utilising “pragmatic” trial designs may overcome some of the economic and time-consuming 
limitations these trials have.   
An example of using a less conventional approach was recently utilised to generate preliminary 
efficacy data regarding exenatide treatment on disease progression in PD.  In the absence of placebo 
control, investigators used a parallel group of patients with moderate stage PD on stable drug 
treatment that were matched to the treatment group, but did not receive injectable therapy – 
allowing a comparison of the novel treatment with best available therapy [50].  Patients were 
followed for 12 months followed by a final assessment 2 months after exenatide withdrawal 
(allowing for any symptomatic effects to dissipate).  Additionally a longer washout period of 12 
months followed the end of the active intervention theoretically enabling any long lasting 
symptomatic or placebo effects to dissipate and was able to be tolerated as patients were on stable 
medication regimes [51].  Although not as robust as a double-blind, placebo controlled trial, this data 
was used to justify further funding for a larger, Phase II study and has suggested that clinically 
informative data might successfully be obtained from patients with PD using standard clinical 
measures, without biomarkers and without a placebo-controlled arm, in a relatively inexpensive way 
[52].   However, as evidenced by previous studies demonstrating the importance of the placebo 
effect in PD patients and particular in clinical trials [35,53,54], there remains understandable 
uncertainty regarding the use of data from studies that do not utilise a placebo-controlled arm.   
Novel techniques such as clinical trial simulation and disease modelling have advanced in recent 
years and could be used to minimise or avoid extrinsic errors in trial design and aid researchers to 
select an appropriate design to utilise. The results of a double-blind, placebo-controlled trial of 
intraputamenal infusion of GDNF as a treatment for PD excluded  the possibility of a clinical effect 
[55], despite encouraging results from previous open label trials. However, although reasons such as 
methodical differences and placebo effect were proposed to explain these discrepancies, further 
analysis of the statistical method suggested the trial was underpowered and therefore incapable of 
drawing conclusions from the seemingly negative results[56].  Disease modelling and simulation can 
now be used to facilitate design of clinical trials and calculate the probability of a specific outcome 
[57].  Using these techniques, a study suggested washout designs may be superior to delayed start 
designs to detect evidence of disease modification (assuming a washout period of at least 3 months) 
[58] though as previously noted, long washout periods can themselves be problematic for untreated 
patients.    
Additionally, using disease progression data from natural history studies and pharmacodynamic and 
pharmacokinetic models, data can be integrated to simulate different trial scenarios for predictive 
purposes.  A clinical trial stimulation model for AD has been recently been developed and accepted 
by the FDA as a quantitative tool that could be used to calculate variables such as sample size, bias 
and power between varying study designs, and if successful, further models regarding PD may be 
developed.   
Reducing inherent errors / variability of data 
Dealing with missing data is a problem inherent to all trials but varying methods can significantly 
affect results.  Recently new statistical methods to overcome methodological issues in the delayed 
start design such as discontinuation rates and missing data to test non inferiority have been 
proposed and successfully applied to Phase 3 AD clinical trial data, suggesting it can control Type 1 
errors and provide robust evidence of disease modifying effects, and this could be utilised in future 
PD trials [36].  
In longitudinal studies, patient dropout is not uncommon but the resulting missing data can be a 
major complicating factor in the analysis, and may have substantial consequences for the 
interpretation of the results [59].  As well as efforts to minimise patient withdrawal, studies have 
shown that Mixed-Effect Model Repeated Measure (MMRM) analysis appears to be a superior 
approach in controlling Type I error rates and minimizing biases, as compared to the more 
traditional “last observation carried forward” (LOCF) ANCOVA analysis [60], and with relevance to 
disease modifying trials, regulatory agencies have recommended the MMRM approach.   
 
Selecting suitable endpoints 
Demonstrating evidence of neuroprotection in pre-clinical studies is relatively straightforward, 
however quantifying neuronal cell death is not a feasible end point in clinical trials and therefore 
demonstrating that a therapy has delayed clinical disease progression or postponed disability is a 
pragmatic and acceptable alternative.    In view of this, alternative surrogate endpoints as markers of 
disease progression have been utilised in previous clinical trials, though all have their own 
advantages and disadvantages.   
Time to onset of event 
The time taken for a drug-naïve patient to require dopaminergic or symptomatic therapy is often 
used in clinical trials as evidence of disease progression.  Although this can be a well-defined, 
measurable endpoint [61] that is not confounded by symptomatic effects from other drugs , a 
notable limitation is that in clinical practice, the decision to start symptomatic therapy can be 
influenced by a number of factors that depend on the patient, physician and care centre.  A study 
showed that almost 50% of patients required dopaminergic therapy before the end of 12 months 
[62], and this was influenced by factors such as level of patient education and emotional state. The 
time to require therapy, therefore, does not necessarily correlate with disease stage or rate of 
progression, and it is often impossible to differentiate whether a delayed need for symptomatic 
treatment reflects symptomatic or neuroprotective effects of the studied drug [61,63].   
The onset of dementia, postural instability and need for residential care are well recognised late 
stage clinical milestones that occur at a similar time from death independent of age of onset [64] 
and as such have been suggested as suitable endpoints to study. However, the interval between 
diagnosis and development of these milestones is extremely heterogeneous; 10-year follow up data 
from the CamPaIGN study showed that although most patients at 10 years had either developed 
dementia or postural instability, 25% of patients still had preserved mobility and cognition[65]. 
Practically speaking this would mean conducting trials with extremely long follow up or selectively 
recruiting patients with advanced disease (with their inherent disadvantages as noted above).  
However, using data from natural history studies patients could be tracked against their individual 
expected disease trajectory which could allow the detection of true disease modification and 
potentially remove the need for control arms [66]. 
Changes in disease rating scales over time 
Measuring the progression of clinical features over time is another commonly used method of 
assessing therapeutic efficacy and these can be divided into those that measure impairment (e.g. 
MDS-UPDRS) , disability (e.g. the Schwab and England Activities of Daily Living (ADL) Scale (S&E) or 
quality of life (e.g. the 39-item Parkinson's disease questionnaire ([PDQ-39]) [67].  Although in 
essence these assess the symptomatic effects at a single time point, repeated measurements 
combined with methods to delineate between symptomatic or disease modifying effects (delayed 
start design, washout etc.) or comparison to control groups can be used to demonstrate delay in 
disease progression.  Additionally, data collected from placebo groups can be a useful resource for 
future trial planning. The MDS-UPDRS is the most widely used and accepted endpoint, is clinically 
relevant to patients, assesses motor and non-motor symptoms, has been validated and calibrated 
against the older UPDRS, has objective instructions for use and uses a certification process to reduce 
inter-rater variability [68,69]. Despite this, use of the MDS-UPDRS as a primary end point has a 
number of issues.  In patients on stable therapy, symptomatic medication influences the assessment 
of the UPDRS Part III (the motor subscale).  Furthermore, being able to define a minimally clinically 
important change in UPDRS scores that is relevant to patients is critical in order to interpret the 
relevance of a statistical change and to aid calculation of sample size for future trials.  The annual 
rate of change of the older UPDRS total score estimated from older interventional trials is around 8-
10 points per year and a minimally relevant clinical change is around 5-8 points, but equivalent rate 
of change for the MDS-UPDRS has not yet been clearly established.  Additionally, a recent study has 
shown that the rate of progression of UPDRS scores is not linear, but rather occurs in three distinct 
phases following diagnosis: improvement, stability, and steady decline [8], and this rate of change is 
also influenced by variables such as age at diagnosis, baseline motor score and cognitive status, 
which are often not controlled for in the analysis.  Also, some symptoms within the scale do not 
progress evenly - data from longitudinal studies have shown that although average UPDRS motor 
scores increased by 1.2 points/year, tremor scores did not change over time [70] – perhaps 
underlining the importance of stratifying patients according to phenotype.   
To increase the chance of detecting a signal of effect, longitudinal assessment of the MDS-UPDRS 
scores are also often supported by measurement of a wide range of secondary end points such as 
scales to assess effects on quality of life, cognition, mood, dyskinesia, gait, and non motor systems.  
Together these can allow detection of effects on non-dopaminergic systems also, as well as motor 
and non-motor symptoms.  The rationale is that any potentially positive effects of disease modifying 
therapy would be more convincing if they are also shown to have benefit across a range of 
dysfunctional neurotransmitter systems.  While these questionnaires are thought to provide a global 
indicator of function, further work is needed to validate their usage as measure of disease 
progression.  Patient diaries as end points in clinical trials have been associated with reduced 
compliance, recall bias and diary fatigue, particularly in patients with cognitive dysfunction and 
depression[71], and often do not correlate with quantitative objective assessments [72,73].  Stage of 
disease can also influence the usefulness of the questionnaires.  A study suggested that UPDRS 
scores correlates well with disease progression, but questionnaires assessing overall disability such 
as the PDQ-39 and Total Functional Capacity scale were not sensitive to change in early disease [47], 
whereas in moderate stage disease, the PDQ-39 summary index was found to be most sensitive to 
change [74].   
Change in imaging markers 
As a result of the limitations of clinical evaluations, many trials have utilised surrogate functional 
imaging markers of the nigrostriatal dopaminergic system as a primary or secondary endpoint to act 
as a measure of disease progression.   Previous studies have measured dopamine terminal function 
by 18F-Dopa PET, or dopamine transporter function, using PET, using tropane-based tracers, or 
single-photon emission computed tomography (SPECT), with a variety of ligands [75,76].  These 
markers have the advantage of being able to detect changes in patients with early disease and are 
more objective than clinical assessments.  However, modalities such as PET imaging are often 
prohibitively expensive, with availability and standization across centres being a further issue.   Also, 
there remain a lot of issues regarding validation and qualification of these methods.  For example, in 
the ELLDOPA trial, using B-CIT SPECT as a surrogate imaging marker, there was faster decline in 
striatal dopamine transporter in patients on L-dopa despite a clear clinical improvement, and other 
trials have demonstrated similar discordant results between imaging and clinical progression [55,77–
79].  Confounding effects of symptomatic drugs on proteins interacting with radioligands has since 
been postulated  as a possible explanation for these effects and has highlighted that there may still 
some way to go before these techniques become accepted as validated biomarkers in efficacy trials 
by regulatory agencies.   
Future directions – reducing variability and improving quality of data 
Research into biomarkers 
Identifying PD-specific, sensitive, validated quantifiable biomarkers are alternatives to subjective 
clinical rating scales and would greatly enhance techniques to measure disease progression and 
therapeutic interventions.  Ongoing research into using patient tissue and fluid biomarkers is 
advancing including CSF analysis (see [80] for review), biochemical tests (see [81] for review) and 
neurophysiological tests (olfaction, motor tests) to investigate measures that most accurately 
measure disease progression but further work is need to validate and qualify their use before they 
are accepted by regulatory agencies.   
There are similar advances in imaging biomarkers - new techniques using 7T MRI, novel MRI 
sequences (utilising a combination of diffusion tensor imaging, T2*-weighted and whole-brain T1-
weighted techniques) , novel PET ligands or transcranial ultrasound have shown promise in early 
identification of patients prior to a clinical diagnosis of PD, though as markers of disease progression, 
results are less convincing. Quantification of abnormal deposition of alpha synclein may be a more 
direct measure of disease progression in PD and a recent study has demonstrated that a novel ligand 
can bind alpha-synuclein fibrils and may be able to be used to monitor disease progression [82].  
Other non-dopaminergic targets may also be relevant - a recent study using 3T MRI scan 
demonstrated that cortical thinning in the temporo-parietal regions could be used as a biomarker of 
mild cognitive impairment in patients with PD progressing towards dementia [15,83].   
Minimising variability / error in assessing endpoints 
The lack of reliable CSF, blood or imaging biomarkers, means that clinical trials currently have to rely 
on clinical endpoints or symptomatic markers to assess disease progression. These measures are 
often insensitive, rely on episodic monitoring which only provides a “snap-shot” of the patient, can 
be influenced by natural disease fluctuation, are subjective and can be prone to inter- and intra-rater 
variability[84], and generally require the patient to attend the research centre to collect the data 
required, incurring expense and burden to the patient, which negatively impacts on patient 
recruitment [85].  Efforts to reduce variability of assessments and the “noise” of the effects of 
symptomatic medication on motor assessment scales include assessing patients after a period of 
overnight drug withdrawal (i.e. in the OFF medication state) though this may impact recruitment as 
some patients are unable to tolerate this.  Similarly, in order to minimise rater variability, some 
studies advocate video recording assessments of MDS-UPDRS motor scale to act a “quality-controls” 
(though this does not affect patient expectation and the size of the placebo effect) and assessing the 
inter-rater reliability at the beginning of each clinical trial and select only those raters who have 
achieved good kappa values [86]. 
The evolution of mobile and online technology means it is now possible to be able to remotely 
collect objective data about disease progression from patients in a continuous and quantitative 
fashion. Using wearable devices, various studies have shown that is possible to collect objective data 
regarding bradykinesia, tremor, dyskinesia, walking, sleep and speech that correlate to severity of 
disease, response to medication and track disease progression [87–90].  A recent study also showed 
that an intelligent closed-loop system integrating a wide range of wearable sensors, allowed 
physicians to remotely monitor the condition changes of the patients, adjust medication schedules, 
and individualize therapy in real-life conditions [91].  
Many of these systems also allow home or continuous monitoring, allowing increasing detection of 
events currently undetectable, being able to capture and incorporate motor fluctuations [88], and 
the need to avoid episodic assessments in the research centre.  Additionally, virtual visits using 
telemedicine can decrease burden on patients, improve patient recruitment; reduce variability in 
assessments and chances for missing data.  Studies have shown that this technique is feasible and 
can offer similar benefits to that of in-person evaluations [92,93].  Although many of these devices 
compare favourably with the “gold standard” of assessments of motor function, the MDS-UPDRS, 
and can provide greater test-retest reliability and sensitivity to change than conventional clinical 
ratings [94], there are current limitations to such approaches.  Some aspects of assessment such as 
rigidity are extremely difficult to assess remotely and these devices remain to be validated in large 
population of patients with PD.  
While most endpoints aim to measure the change in clinical rating scales over time, a recent study 
has suggested a novel composite binary endpoint measuring mortality and dependency [67].  The 
novel measure was found to be clinically relevant, sensitive to disease progression from patient’s 
already on stable symptomatic therapy (minimising patient drop out) and requires smaller sample 
sizes enabling trials to be more cost effective, though further validation in larger cohorts is required.  
Yet despite all these refinements to optimise endpoints, there remains the question of whether 
positive results demonstrated in a given population during a (relatively) short duration disease 
modification trial can be extrapolated throughout the course of the disease in other populations.  
The duration of many disease modification trials is determined by a number of factors but must be 
sufficiently long enough to allow the adequate detection of the expected treatment effect in the 
sample size being studied while also taking into consideration the many technical and economic 
factors as outlined above.  As a result, any observed changes in disability are often small and the 
clinical relevance in wider populations and at varying stages of the disease is uncertain.   
Adding the proposed experimental intervention to existing stable symptomatic therapies in a large, 
placebo controlled, longitudinal “one-period” trial, using clinical milestones and global measures of 
patient quality of life as endpoints would be one pragmatic method of overcoming these limitations 
[3] but incur many of the same issues as stated above and require considerable investment and 
resources.  
Conclusions 
Despite the continued failure to date of finding any disease modifying therapy in PD, encouragement 
can be sought from parallel work in the field of research into multiple sclerosis.  MS, like PD, is a 
heterogeneous, (ultimately) neurodegenerative disease with marked variability in clinical phenotype 
as well as radiological pathological and genetic phenotypes.  Yet despite such differences remarkable 
progress has been made in the development of drugs that can alter the trajectory of some forms of 
MS.  However developing and utilising a study design that is able to detect evidence of delayed 
disease progression in PD is challenging. Although double-blind, placebo controlled trials remain the 
gold standard of trial design, more pragmatic designs have demonstrated that useful data can be 
gathered quickly and cost-effectively, paving the way for more robust studies.  Reducing variability in 
data collection may be possible with advances in technology enabling efficient, objective and 
continuous data collection describing a wide range of symptoms.  Additionally improved , and where 
necessary targeted patient selection may be crucial for future trials, with consideration that cohorts 
may be better focused on participants most likely to show a measurable change over the course of 
study. In parallel, a variety of outcome measures that reflect the diversity of range of PD phenotypes 
are needed that are sensitive to the intervention and vary over time.  Similarly, the establishment of 
valid biomarkers will alter how clinical trials measure disease progression and ongoing longitudinal 
studies may enable early identification of patients who would be most likely to gain from any 
neuroprotective therapies.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 - Patient suitability for disease modifying clinical trials 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
De novo untreated patients 
 
Symptomatic stable treated patients 
Advantages Advantages 
 
 Considered “early” disease – more salvageable  
neuronal population (30-50% of neurons lost)[1,2]  
 No cofounding effects of symptomatic medication 
 Minimal clinical fluctuation 
 
 Easy to identify and recruit into trials 
 Clinical changes in disability more likely to be 
detected rating scales 
 Less likely to include recruiting patients without 
idiopathic PD 
Disadvantages Disadvantages 
 
 Fewer in number, recruitment is slow, incurring 
greater expense 
 Patients with greater disability at baseline will 
have shorter “untreated” tolerable window  - 
narrowing chance to detect disease modifying 
effects 
 Maintaining patients with mounting disability on 
placebo may be unethical 
 Increasing disability in some patients may induce 
high dropout rate – leading to over representation 
of patients with slower disease course 
 Drop out may lead to difficulties with data analysis 
 Risk of including patients with atypical forms of 
parkinsonism (and alternative pathologies)  - 10% 
of patients clinically diagnosed with early PD have 
SWEDD who majority do not go to develop PD 
[3,4] 
 Clinical rating scales at early stage disease may not 
be sensitive to detect changes in disability and 
create floor effects 
 Heterogeneous clinical progression 
 
 Symptoms influenced by effects of medication 
 Clinical fluctuation and variable response to 
medication make longitudinal assessments difficult  
 “Ceiling” effects of clinical rating scales such as 
UPDRS make changes in advanced disability 
difficult  
 In trials with placebo arm, may exhibit increased 
magnitude of placebo effect 
 Advanced neurodegeneration may mean that any 
neuroprotective therapies may be “too little, too 
late” 
 Greater number of co-morbidities in advanced 
population may preclude lengthy longitudinal 
assessments [5] 
 Heterogeneous clinical progression 
Figure 1 - Methods to stratify patients prior to selection in Phase 3 disease modification trials to reduce heterogeneity. 
 
 
 
 Figure 2 - Common trial designs used in Phase 3 disease modification trials. 
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